Safety and Pharmacokinetic Profiles of Subcutaneous Administration of Beta-Lactams: A Systematic Review.

IF 1.5 4区 医学 Q4 MICROBIOLOGY
New Microbiologica Pub Date : 2024-11-01
Chiara Moreal, Stefania Chiappinotto, George G Zhanel, Simone Lanini, Luca Montanari, Alvisa Palese, Carlo Tascini
{"title":"Safety and Pharmacokinetic Profiles of Subcutaneous Administration of Beta-Lactams: A Systematic Review.","authors":"Chiara Moreal, Stefania Chiappinotto, George G Zhanel, Simone Lanini, Luca Montanari, Alvisa Palese, Carlo Tascini","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Beta-lactams are extensively used antibiotics known for their safety and effectiveness. The rise in patients who receive care in outpatient settings has increased the interest in subcutaneous administration (SA). The aim of the study is to assess the safety and pharmacokinetic (PK) profiles of SA of beta-lactams compared with other routes. The protocol was registered in the PROSPERO database and the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines were followed. Online databases were searched, and the quality of the eligible studies was assessed. The data extracted related to adverse events (AEs) and PK were summarised narratively. Sixteen studies were included. The reported AEs were generally mild, localised, and temporary. Although SA and intravenous administration had similar PK profiles, SA resulted in lower peak drug concentrations and slower absorption. Heterogeneity in the populations, medication delivery, outcome measures, and methodological quality emerged across the studies. The mild severity of AEs suggests that SA is a viable route. Additionally, SA appears to demonstrate effective PK profiles and delays drug release, with potential to reduce the dosing frequency and prolong the therapeutic effects. SA of beta-lactams is a promising viable alternative to intravenous administration, potentially enhancing treatment in the outpatient and long-term care settings.</p>","PeriodicalId":54723,"journal":{"name":"New Microbiologica","volume":"47 3","pages":"227-242"},"PeriodicalIF":1.5000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"New Microbiologica","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Beta-lactams are extensively used antibiotics known for their safety and effectiveness. The rise in patients who receive care in outpatient settings has increased the interest in subcutaneous administration (SA). The aim of the study is to assess the safety and pharmacokinetic (PK) profiles of SA of beta-lactams compared with other routes. The protocol was registered in the PROSPERO database and the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines were followed. Online databases were searched, and the quality of the eligible studies was assessed. The data extracted related to adverse events (AEs) and PK were summarised narratively. Sixteen studies were included. The reported AEs were generally mild, localised, and temporary. Although SA and intravenous administration had similar PK profiles, SA resulted in lower peak drug concentrations and slower absorption. Heterogeneity in the populations, medication delivery, outcome measures, and methodological quality emerged across the studies. The mild severity of AEs suggests that SA is a viable route. Additionally, SA appears to demonstrate effective PK profiles and delays drug release, with potential to reduce the dosing frequency and prolong the therapeutic effects. SA of beta-lactams is a promising viable alternative to intravenous administration, potentially enhancing treatment in the outpatient and long-term care settings.

β-内酰胺类药物皮下注射的安全性和药代动力学特征:系统回顾
β-内酰胺类抗生素因其安全性和有效性而被广泛使用。随着在门诊接受治疗的患者人数增加,人们对皮下注射(SA)的兴趣也随之增加。本研究旨在评估与其他途径相比,β-内酰胺类药物皮下注射的安全性和药代动力学(PK)特征。研究方案已在 PROSPERO 数据库中注册,并遵循了《系统综述和元分析首选报告项目》指南。对在线数据库进行了检索,并对符合条件的研究进行了质量评估。对提取的不良事件(AEs)和PK相关数据进行了叙述性总结。共纳入 16 项研究。所报告的不良反应一般较轻微、局部且暂时。虽然 SA 和静脉给药具有相似的 PK 曲线,但 SA 导致峰值药物浓度较低且吸收较慢。各项研究在研究对象、给药方式、结果测量和方法质量等方面都存在异质性。不良反应的严重程度较轻,这表明 SA 是一种可行的途径。此外,SA 似乎显示出有效的 PK 曲线,并能延迟药物释放,有可能减少用药频率并延长疗效。β-内酰胺类药物的 SA 是一种替代静脉给药的可行方法,具有广阔的前景,有可能提高门诊和长期护理环境中的治疗效果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
New Microbiologica
New Microbiologica 生物-微生物学
CiteScore
2.20
自引率
5.60%
发文量
40
审稿时长
6-12 weeks
期刊介绍: The publication, diffusion and furtherance of research and study on all aspects of basic and clinical Microbiology and related fields are the chief aims of the journal.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信